A Phase 2 interventional study of Enfortumab vedotin in Carcinoma, Transitional Cell, Urinary Bladder Neoplasms and Urologic Neoplasms, sponsored by Astellas Pharma Inc. Completed at 81 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-27.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell — 10 open to participants now, 15 under way, 1 of them phase 3. enfortumab vedotin · Carcinoma, Transitional Cell.
Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 10 in phase 2, and was the 2nd registered.
633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.
Browse Carcinoma, Transitional Cell studies →10 of the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell are open now, in 6 countries. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Astellas Pharma Global Development, Inc. · Sites in United States, Canada, Korea, Republic of and 1 more country
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
University of Oklahoma · Sites in United States
Ages 18+
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
enfortumab vedotin: first FDA approval 2019 (PADCEV), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, enfortumab vedotin is the treatment under test here. Read study by study →
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 14 · Phase 3 1 · Phase 4 1
First in 2017; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 50 across 499 interventional studies indexed under Carcinoma, Transitional Cell.
Median enrollment 49 across the 20 interventional studies. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 20 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
Astellas Pharma Inc has 8 studies filed under Carcinoma, Transitional Cell — fewer than ten, so there is no comparison to draw.
6 of the studies testing enfortumab vedotin in Carcinoma, Transitional Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04963153National Cancer Institute (NCI)Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | 2026-12-01 |
| NCT06862219Astellas Pharma Global Development, Inc.A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | 2026-12-31 |
| NCT04724018Dana-Farber Cancer InstituteSacituzumab Govitecan Plus EV in Metastatic UC | 2027-02-01 |
| NCT07647289Peking University Third HospitalEV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC | 2027-04 |
| NCT05239624Memorial Sloan Kettering Cancer CenterEnfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 20 studies testing enfortumab vedotin in Carcinoma, Transitional Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body.
This clinical trial will enroll patients who were previously treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). Some CPIs have been approved for the treatment of urothelial cancer.
This study will test if the cancer shrinks with treatment. This study will also look at the side effects of the drug. A side effect is a response to a drug that is not part of the treatment effect.
Patients who sign up for this trial must also fall into one of these categories:
Japan Pharmaceuticals and Medical Devices Agency (PMDA) has approved enfortumab vedotin (Padcev) for the treatment of advanced urothelial cancer. The study will continue as a post marketing study in Japan.
This study will examine the safety and anticancer activity of enfortumab vedotin given intravenously to patients with locally advanced or metastatic urothelial cancer who previously received a CPI and either previously received platinum-containing chemotherapy (Cohort 1) or are platinum-naïve and cisplatin-ineligible (Cohort 2). Patients who received platinum in the adjuvant/neoadjuvant setting and did not progress within 12 months of completion will be considered platinum-naïve. Approximately 100 patients are expected to be enrolled in each cohort. The primary goal of the study is to determine the confirmed ORR of enfortumab vedotin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Enfortumab vedotin on days 1, 8 and 15 every 28 days
Drug: Enfortumab vedotin
Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
Also known as: ASG-22CE, ASG-22ME
Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR)
ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Duration of Objective Response (DOR) Per BICR
The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause, whichever comes first. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. DOR was analyzed using Kaplan-Meier methodology.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Progression-Free Survival (PFS) Per BICR
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
ORR Per Investigator Assessment
ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
DOR Per Investigator Assessment
CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
PFS Per Investigator Assessment
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
Time frame: Cohort 1: median follow-up time: 10.15 months (range 0.49, 16.46); Cohort 2: median follow up time: 13.4 months (range 0.33 to 29.27)
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Hematology)
A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
Number of Participants With Treatment-Emergent Laboratory Abnormalities (Serum Chemistry)
A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based NCI CTCAE version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
Time frame: The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
Incidence of Antitherapeutic Antibody (ATA)
Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if \>=2 consecutive samples were confirmed as positive.
Time frame: The median duration of treatment was 4.60 months for Cohort 1 [full range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [full range: 0.3, 24.6 months]
Disease Control Rate at 16 Weeks (DCR16) Per BICR
Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Up to Week 16
DCR16 Per Investigator Assessment
Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Up to Week 16
Overall Survival (OS): Primary Analysis
OS is defined as the time from first dose of enfortumab vedotin to death from any cause.
Time frame: Cohort 1 median follow-up time: 28.4 months [range 0.49, 32.62]; Cohort 2 median follow up time: 13.4 months [range 0.33 to 29.27]
Number of Participants With Adverse Events (AEs): Primary Analysis
AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.
Time frame: The median duration of treatment was 4.60 months for Cohort 1 [range: 0.5, 29.4 months] and 5.98 months for Cohort 2 [range: 0.3, 24.6 months]
Pharmacokinetics (PK) Parameter for Enfortumab Vedotin: Maximum Concentration (Cmax) (Serum)
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for Enfortumab Vedotin: Time to Maximum Concentration (Tmax) (Serum)
Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for Enfortumab Vedotin: Area Under Concentration-Time Curve (AUC) (Serum)
AUC was derived from the PK blood samples collected.
Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
PK Parameter for Free Monomethyl Auristatin E (MMAE): Cmax (Plasma)
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for Free MMAE: Tmax (Plasma)
Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for Free MMAE: AUC (Plasma)
AUC was derived from the PK blood samples collected.
Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
PK Parameter for Total Antibody (TAb): Cmax (Serum)
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for TAb: Tmax (Serum)
Tmax was derived from the PK blood samples collected. Time of maximum concentration corresponds to the end of infusion sample time. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
Time frame: Collected during cycle 1 and 2 of treatment (each cycle=28 days) at Day 1 pre-dose and end of infusion, Day 3, Day 8 pre-dose and end of infusion, Day 15 pre-dose and end of infusion, Day 17, and Day 22
PK Parameter for TAb: AUC (Serum)
AUC was derived from the PK blood samples collected.
Time frame: AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)
Number of Participants With Adverse Events (AEs): Final Analysis
AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.
Time frame: Cohort 1: median treatment duration time: 4.60 months (range 0.5, 43.0); Cohort 2: median treatment duration time: 5.98 months (range 0.3 to 25.8)
Overall Survival (OS): Final Analysis
OS is defined as the time from first dose of enfortumab vedotin to death from any cause.
Time frame: Cohort 1: median follow-up: 61.0 months (range 59.63, 62.36); Cohort 2: median follow-up time: 45.8 months (range 44.91 to 48.95)
| Milestone | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Started | 128 | 91 |
| Treated | 125 | 89 |
| Completed | 0 | 0 |
| Not completed | 128 | 91 |
| Withdrew: Withdrawal by subject | 9 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Death | 104 | 72 |
| Withdrew: Study closed in 2023,as all milestones reached, majority of participants completed 5 years follow-up | 12 | 12 |
| Withdrew: Other | 2 | 2 |
ORR was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| Percentage of Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) | 44 (35.1 to 53.2) | 51.7 (40.8 to 62.4) |
The time from first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of progressive disease (PD) or to death due to any cause, whichever comes first. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. DOR was analyzed using Kaplan-Meier methodology.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Duration of Objective Response (DOR) Per BICR | 7.6 (6.34 to NA) | 10.9 (5.78 to NA) |
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Progression-Free Survival (PFS) Per BICR | 5.8 (4.93 to 7.46) | 5.8 (5.03 to 8.28) |
ORR was defined as the percentage of participants with confirmed CR or PR according to RECIST 1.1. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
| Percentage of Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| ORR Per Investigator Assessment | 39 (30.6 to 48.3) | 50.6 (39.8 to 61.3) |
CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| DOR Per Investigator Assessment | 7.9 (5.95 to NA) | 10.7 (5.85 to 16.59) |
The time from start of study treatment to first documentation of objective tumor progression (PD per RECIST 1.1), or to death due to any cause, whichever comes first. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| PFS Per Investigator Assessment | 5.8 (4.93 to 7.46) | 7.2 (5.42 to 7.69) |
A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based on National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Hemoglobin decreased (all grades) | 52 | 39 |
| Hemoglobin decreased (grade 3-4) | 12 | 4 |
| Leukocytes decreased (all grades) | 33 | 28 |
| Leukocytes decreased (grade 3-4) | 5 | 4 |
| Lymphocytes decreased (all grades) | 55 | 61 |
| Lymphocytes decreased (grade 3-4) | 12 | 13 |
| Lymphocytes increased (all grades) | 0 | 1 |
| Lymphocytes increased (grade 3-4) | 0 | 0 |
| Neutrophils decreased (all grades) | 28 | 27 |
| Neutrophils decreased (grade 3-4) | 7 | 8 |
| Platelets decreased (all grades) | 39 | 20 |
| Platelets decreased (grade 3-4) | 0 | 0 |
A treatment-emergent laboratory abnormality is a value increases or decrease by 1 toxicity grade after the first study dose. Abnormalities were graded based NCI CTCAE version 4.03 - Grade 1: mild; Grade 2: moderate; Grade 3: severe or clinically significant; Grade 4: life-threatening.
| Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Alanine aminotransferase increased (all grades) | 34 | 26 |
| Alanine aminotransferase increased (grade 3-4) | 1 | 0 |
| Albumin decreased (all grades) | 38 | 16 |
| Albumin decreased (grade 3-4) | 1 | 0 |
| Alkaline phosphatase increased (all grades) | 21 | 12 |
| Alkaline phosphatase increased (grade 3-4) | 1 | 0 |
| Aspartate aminotransferase increased (all grades) | 79 | 52 |
| Aspartate aminotransferase increased (grade 3-4) | 3 | 2 |
| Bilirubin increased (all grades) | 13 | 5 |
| Bilirubin increased (grade 3-4) | 1 | 0 |
| Calcium decreased (all grades) | 15 | 7 |
| Calcium decreased (grade 3-4) | 0 | 0 |
| Calcium increased (all grades) | 1 | 7 |
| Calcium increased (grade 3-4) | 0 | 3 |
| Creatinine increased (all grades) | 73 | 46 |
| Creatinine increased (grade 3-4) | 2 | 3 |
| Glucose decreased (all grades) | 32 | 26 |
| Glucose decreased (grade 3-4) | 0 | 0 |
| Glucose increased (all grades) | NA | NA |
| Glucose increased (grade 3-4) | 10 | 11 |
| Phosphate decreased (all grades) | 42 | 22 |
| Phosphate decreased (grade 3-4) | 12 | 6 |
| Potassium decreased (all grades) | 25 | 11 |
| Potassium decreased (grade 3-4) | 2 | 1 |
| Potassium increased (all grades) | 13 | 17 |
| Potassium increased (grade 3-4) | 0 | 5 |
| Sodium decreased (all grades) | 54 | 28 |
| Sodium decreased (grade 3-4) | 10 | 6 |
| Sodium increased (all grades) | 2 | 1 |
| Sodium increased (grade 3-4) | 0 | 0 |
| Urate increased (all grades) | 32 | 38 |
| Urate increased (grade 3-4) | 8 | 8 |
| Amylase increased (all grades) | 20 | 18 |
| Amylase increased (grade 3-4) | 1 | 3 |
| Lipase increased (all grades) | 37 | 32 |
| Lipase increased (grade 3-4) | 12 | 10 |
Participants who were tested positive for ATA at any time post-baseline were considered to be transiently positive or persistently positive if \>=2 consecutive samples were confirmed as positive.
| Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Baseline Negative — Negative post-baseline | 109 | 76 |
| Baseline Negative — Transiently positive post-baseline | 2 | 3 |
| Baseline Negative — Persistently positive post-baseline | 1 | 1 |
| Baseline Positive — Negative post-baseline | 1 | 1 |
| Baseline Positive — Transiently positive post-baseline | 1 | 0 |
| Baseline Positive — Persistently positive post-baseline | 0 | 0 |
Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Disease Control Rate at 16 Weeks (DCR16) Per BICR | 50 (41.3 to 59.5) | 58.4 (47.5 to 68.8) |
Percentage of participants with CR, PR, or stable disease (SD) at Week 16 visit. CR is defined as disappearance of all target lesions and non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR is defined as a \>=30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 0.5 cm. The appearance of one or more new lesions is also considered progression. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| DCR16 Per Investigator Assessment | 55 (46.0 to 64.1) | 64.0 (53.2 to 73.9) |
OS is defined as the time from first dose of enfortumab vedotin to death from any cause.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Overall Survival (OS): Primary Analysis | 12.4 (9.46 to 15.57) | 14.7 (10.51 to 18.20) |
AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.
| Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Any treatment-emergent AEs (TEAEs) | 125 | 89 |
| Treatment-related TEAEs | 117 | 86 |
| Any grade 3-5 TEAEs | 93 | 62 |
| Treatment-related grade 3-5 TEAEs | 70 | 49 |
| Any serious TEAEs | 59 | 35 |
| Treatment-related serious TEAEs | 24 | 15 |
| Any TEAEs leading to treatment discontinuation | 21 | 18 |
| Treatment-related TEAEs leading to treatment discontinuation | 15 | 14 |
| Any TEAEs leading to death | 7 | 8 |
| Treatment-related TEAEs leading to death | 0 | 3 |
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Microgram per milliliter (µg/mL) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 26.6 ± 28.5 | 23.9 ± 24.4 |
| Cycle 1, Day 15 | 26.0 ± 28.3 | 21.7 ± 29.7 |
| Cycle 2, Day 1 | 24.5 ± 31.4 | 22.0 ± 24.5 |
| Cycle 2, Day 15 | 26.3 ± 25.2 | 20.7 ± 27.4 |
Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Days | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 0.0278 (0.010 to 0.052) | 0.0264 (0.021 to 0.088) |
| Cycle 1, Day 15 | 0.0285 (0.014 to 0.054) | 0.0264 (0.014 to 0.084) |
| Cycle 2, Day 1 | 0.0264 (0.011 to 0.042) | 0.0264 (0.015 to 0.074) |
| Cycle 2, Day 15 | 0.0285 (0.020 to 0.115) | 0.0257 (0.010 to 0.047) |
AUC was derived from the PK blood samples collected.
| Day*microgram per milliliter | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| 7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1 | 34.6 ± 34.0 | 33.5 ± 41.4 |
| AUC(d0-7) - Cycle 1, Day 8 | 31.3 ± 43.8 | 26.3 ± 46.0 |
| AUC(d0-7) - Cycle 2, Day 1 | 36.4 ± 36.7 | 32.0 ± 30.0 |
| AUC(d0-7) - Cycle 2, Day 8 | 35.9 ± 41.2 | 27.8 ± 35.8 |
| 14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 8 | 34.7 ± 44.7 | 30.9 ± 47.5 |
| AUC(d0-14) - Cycle 2, Day 15 | 41.2 ± 40.4 | 33.1 ± 36.6 |
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Nanogram per milliliter | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 3.1 ± 67.0 | 2.6 ± 57.8 |
| Cycle 1, Day 15 | 3.9 ± 64.8 | 3.5 ± 51.8 |
| Cycle 2, Day 1 | 2.4 ± 57.4 | 2.2 ± 60.8 |
| Cycle 2, Day 15 | 3.0 ± 64.8 | 2.9 ± 59.9 |
Tmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Days | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 1.9 (1 to 5) | 1.9 (1 to 4) |
| Cycle 1, Day 15 | 2.0 (1 to 11) | 1.9 (1 to 9) |
| Cycle 2, Day 1 | 2.0 (1 to 5) | 1.8 (1 to 5) |
| Cycle 2, Day 15 | 1.9 (1 to 9) | 1.9 (1 to 10) |
AUC was derived from the PK blood samples collected.
| Day*nanogram per milliliter | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| 7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1 | 14.1 ± 81.7 | 13.0 ± 64.1 |
| AUC(d0-7) - Cycle 1, Day 8 | 19.1 ± 79.1 | 18.1 ± 65.0 |
| AUC(d0-7) - Cycle 2, Day 1 | 11.3 ± 58.0 | 10.6 ± 65.0 |
| AUC(d0-7) - Cycle 2, Day 8 | 14.9 ± 64.7 | 15.3 ± 60.2 |
| 14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 15 | 25.9 ± 74.7 | 22.6 ± 76.4 |
| AUC(d0-14) - Cycle 2, Day 15 | 19.1 ± 61.2 | 21.3 ± 65.0 |
Cmax was derived from the PK blood samples collected. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Microgram per milliliter | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 26.6 ± 30.4 | 26.4 ± 23.4 |
| Cycle 1, Day 15 | 30.9 ± 22.9 | 27.3 ± 25.7 |
| Cycle 2, Day 1 | 26.2 ± 30.5 | 26.3 ± 23.8 |
| Cycle 2, Day 15 | 30.2 ± 22.7 | 27.1 ± 28.2 |
Tmax was derived from the PK blood samples collected. Time of maximum concentration corresponds to the end of infusion sample time. Day 1 data informed by samples collected on Day 1, Day 3, and Day 8. Day 15 data informed by samples collected on Day 15, Day 17, and Day 22.
| Days | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Cycle 1, Day 1 | 0.0278 (0.010 to 0.052) | 0.0264 (0.021 to 0.088) |
| Cycle 1, Day 15 | 0.0285 (0.014 to 0.054) | 0.0264 (0.014 to 0.084) |
| Cycle 2, Day 1 | 0.0264 (0.011 to 0.042) | 0.0264 (0.015 to 0.074) |
| Cycle 2, Day 15 | 0.0285 (0.020 to 0.115) | 0.0257 (0.010 to 0.047) |
AUC was derived from the PK blood samples collected.
| Day*microgram per milliliter | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| 7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1 | 63.4 ± 33.6 | 66.8 ± 34.3 |
| AUC(d0-7) - Cycle 1, Day 8 | 77.6 ± 35.2 | 72.3 ± 37.9 |
| AUC(d0-7) - Cycle 2, Day 1 | 73.2 ± 33.5 | 72.9 ± 26.4 |
| AUC(d0-7) - Cycle 2, Day 8 | 87.9 ± 30.6 | 81.0 ± 30.9 |
| 14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 15 | 98.1 ± 38.8 | 91.1 ± 40.3 |
| AUC(d0-14) - Cycle 2, Day 15 | 113.0 ± 33.8 | 109.7 ± 41.5 |
AE=untoward medical occurrence associated with use of study intervention, whether or not considered related. Treatment emergent adverse event (TEAE)=newly occurring/worsening AE after first dose of study treatment, within 30 days after last dose. According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03: Grade(G)3=severe AE, G4=life-threatening, urgent intervention indicated, G5=death related to AE. Participants who discontinued treatment due to treatment related TEAEs captured under TEAEs leading to treatment discontinuation. SAE=event at any dose led to death;life-threatening;required inpatient hospitalization/prolongation of existing hospitalization; persistent/significant disability/incapacity; congenital anomaly/birth defect/ important medical event. Treatment related AEs, SAEs, deaths also included. Treatment relatedness was judged by investigator.
| Participants | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Any treatment-emergent AEs (TEAEs) | 125 | 89 |
| Treatment-related TEAEs | 117 | 86 |
| Any grade 3-5 TEAEs | 93 | 62 |
| Treatment-related grade 3-5 TEAEs | 70 | 49 |
| Any serious TEAEs | 59 | 35 |
| Treatment-related serious TEAEs | 24 | 15 |
| Any TEAEs leading to treatment discontinuation | 22 | 21 |
| Treatment-related TEAEs leading to treatment discontinuation | 16 | 17 |
| Any TEAEs leading to death | 7 | 8 |
| Treatment-related TEAEs leading to death | 0 | 3 |
OS is defined as the time from first dose of enfortumab vedotin to death from any cause.
| Months | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Overall Survival (OS): Final Analysis | 12.4 (9.46 to 15.57) | 15.6 (11.24 to 20.37) |
Collected over Cohort 1: maximum up to 62.36 months of follow-up; Cohort 2: maximum up to 48.95 months of follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enfortumab Vedotin - Cohort 1 | 104/125 (83.2%) | 59/125 (47.2%) | 123/125 (98.4%) |
| Enfortumab Vedotin - Cohort 2 | 72/89 (80.9%) | 35/89 (39.3%) | 88/89 (98.9%) |
| Event | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| Acute kidney injuryRenal and urinary disorders | 4/125 | 9/89 |
| CellulitisInfections and infestations | 6/125 | 0/89 |
| Urinary tract infectionInfections and infestations | 6/125 | 3/89 |
| SepsisInfections and infestations | 4/125 | 4/89 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/125 | 1/89 |
| DiarrhoeaGastrointestinal disorders | 3/125 | 3/89 |
| PneumoniaInfections and infestations | 3/125 | 3/89 |
| Transitional cell carcinoma metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/125 | 3/89 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/125 | 0/89 |
| Abdominal painGastrointestinal disorders | 3/125 | 1/89 |
| Event | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 |
|---|---|---|
| AlopeciaSkin and subcutaneous tissue disorders | 64/125 | 48/89 |
| Peripheral sensory neuropathyNervous system disorders | 54/125 | 47/89 |
| FatigueGeneral disorders | 66/125 | 40/89 |
| Decreased appetiteMetabolism and nutrition disorders | 64/125 | 35/89 |
| NauseaGastrointestinal disorders | 56/125 | 26/89 |
| DiarrhoeaGastrointestinal disorders | 52/125 | 30/89 |
| DysgeusiaNervous system disorders | 49/125 | 27/89 |
| AnaemiaBlood and lymphatic system disorders | 44/125 | 34/89 |
| Weight decreasedInvestigations | 40/125 | 31/89 |
| PruritusSkin and subcutaneous tissue disorders | 34/125 | 31/89 |
Safety population included all participants who received any amount of enfortumab vedotin.
| Age, Continuous(Years) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| Median | 69.0 (40 to 84) | 75.0 (49 to 90) | 72.0 (40 to 90) |
| Sex: Female, Male(Participants) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| Female | 37 | 23 | 60 |
| Male | 88 | 66 | 154 |
| Ethnicity (NIH/OMB)(Participants) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 118 | 83 | 201 |
| Unknown or Not Reported | 2 | 5 | 7 |
| Race (NIH/OMB)(Participants) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 11 | 20 | 31 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 106 | 62 | 168 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 7 | 13 |
| Region of Enrollment(Participants) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| North America | 117 | 57 | 174 |
| Europe | 0 | 14 | 14 |
| East Asia | 8 | 18 | 26 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Enfortumab Vedotin - Cohort 1 | Enfortumab Vedotin - Cohort 2 | Total |
|---|---|---|---|
| 0 | 40 | 37 | 77 |
| 1 | 85 | 41 | 126 |
| 2 | 0 | 11 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2017 to primary completion in Oct 2020, 36 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
Of 119 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's 36 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enfortumab vedotin
Carcinoma, Transitional Cell →